SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Telik, Inc. Announces the Results of Genetic Signature Studies of Myelodysplastic Syndrome Patients Likely to Respond to Telintra(R) (Ezatiostat Hydrochloride, TLK199) at the Annual Meeting of the American Society of Hematology